Addressing Shortcomings of AAV Gene Therapies for Muscular Dystrophy
Official title: Addressing Shortcomings of AAV GeneTherapies for the Muscular Dystrophies
Funded at University of Florida · NIH-11310128 · Data updated 2026-11-12
A national research center is working to improve AAV-based gene therapies for Duchenne and related muscular dystrophies so that patients may get safer, more effective treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | September 25, 2005 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,290,269 |
| NIH project number | 5P50HD119693-21 |
| Project ID | NIH-11310128 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adults with Duchenne muscular dystrophy or limb-girdle muscular dystrophy who may be eligible for future gene therapy trials.
✕Less likely to help
People with muscular dystrophy who are not candidates for gene therapy or who do not respond to AAV-based approaches may not benefit.
What this research studies
This program focuses on making AAV-delivered gene therapies safer and more effective for people with muscular dystrophies. Researchers will optimize compact utrophin-dystrophin chimeric genes that fit into a single AAV vector for muscles and heart, using animal models and human iPSC-derived heart tissues. They will also develop better AAV capsids and transgenes to reduce immune reactions, and test vectors for sarcoglycan deficiency with improved expression and stability. A clinical study component will track skeletal and heart muscle changes in treated individuals to inform future use in patients.
Why it matters
Potential benefit: If successful, the work could lead to safer, more effective AAV gene therapies for Duchenne and limb-girdle muscular dystrophy patients.
How similar studies have gone: Previous AAV gene therapy efforts informed this program, but the integration of novel miniaturized transgenes and optimized capsids represents an advancing step.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Sweeney, H Lee — University of Florida
- Study coordinator: Sweeney, H Lee
Related research
Other NIH-funded projects on the same topics.
-
Noninvasive breathing imaging to guide care for people with muscular dystrophy
A noninvasive imaging tool called electrical impedance tomography (EIT) will be studied to help decide when to start noninvasive ventilation for people with muscular dystrophy.
-
Bicistronic gene therapy for limb girdle muscular dystrophy type R9
A patient-facing overview of a first-in-class gene therapy approach using two genes delivered by AAV to help people with LGMDR9.
-
Understanding why scarring happens in muscular dystrophy muscles
Researchers are studying why scar tissue forms in muscles affected by muscular dystrophy and how to slow or reverse it in patients.
-
Two-gene AAV therapy for Limb-Girdle Muscular Dystrophy R9
Developing a two-gene AAV gene therapy to replace the faulty gene and rebuild muscle for people with LGMDR9 (Limb Girdle Muscular Dystrophy Type R9).
-
Improving Gene Therapies for Muscular Dystrophies
This center is working to improve gene therapies for Duchenne and Limb Girdle Muscular Dystrophy, aiming to make them safer and more effective for patients.
-
Stopping Muscle Scarring in Muscular Dystrophies
This project explores how muscle scarring, called fibrosis, develops in muscular dystrophies like Duchenne MD, hoping to find new ways to help muscles heal better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.